Autologous platelet gel improves bone reconstruction of large defects in patients with Bone Giant Cell Tumors

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aim: Giant cell tumors are mostly benign but locally aggressive tumors. The excision of bone tumors can result in large defects, therefore bone reconstruction is still one the most demanding procedures in orthopedic surgery. Our study addresses the opportunity for improving surgical outcome by employing β-Tricalcium phosphate (β-TCP) with platelet-rich plasma (PRP) at the surgical site. Patients and Methods: We included 16 patients with giant cell tumors. After adjuvant therapy, the cavity was reconstructed with β-TCP, bone graft material (ActifuserR Granules Baxter) and platelet gel application. Results: Our explorative analysis suggests a positive effect of PRP on surgical outcome in patients with giant cell tumors treated with curettage. Conclusion: Use of platelet gel as an adjuvant significantly reduces the time required for bone healing following intralesional treatment of benign giant cell tumors, and achieves good functional results without promoting local recurrence.

Original languageEnglish
Pages (from-to)533-540
Number of pages8
JournalIn Vivo
Volume29
Issue number5
Publication statusPublished - Sep 1 2015

Fingerprint

Giant Cell Tumor of Bone
Giant Cell Tumors
Platelets
Tumors
Bone
Blood Platelets
Gels
Bone and Bones
Defects
Platelet-Rich Plasma
Curettage
Orthopedics
Plasmas
Neoplasms
Transplants
Recurrence
Grafts
Surgery
Therapeutics

Keywords

  • Curettage
  • Giant Cell Tumor Of Bone
  • Growth Factors
  • Loss Of Substance
  • Platelet-Rich Plasma
  • Regenerative Medicine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

@article{57f3d26d0e8a4b11b0ea746816930c09,
title = "Autologous platelet gel improves bone reconstruction of large defects in patients with Bone Giant Cell Tumors",
abstract = "Background/Aim: Giant cell tumors are mostly benign but locally aggressive tumors. The excision of bone tumors can result in large defects, therefore bone reconstruction is still one the most demanding procedures in orthopedic surgery. Our study addresses the opportunity for improving surgical outcome by employing β-Tricalcium phosphate (β-TCP) with platelet-rich plasma (PRP) at the surgical site. Patients and Methods: We included 16 patients with giant cell tumors. After adjuvant therapy, the cavity was reconstructed with β-TCP, bone graft material (ActifuserR Granules Baxter) and platelet gel application. Results: Our explorative analysis suggests a positive effect of PRP on surgical outcome in patients with giant cell tumors treated with curettage. Conclusion: Use of platelet gel as an adjuvant significantly reduces the time required for bone healing following intralesional treatment of benign giant cell tumors, and achieves good functional results without promoting local recurrence.",
keywords = "Curettage, Giant Cell Tumor Of Bone, Growth Factors, Loss Of Substance, Platelet-Rich Plasma, Regenerative Medicine",
author = "Giovanna Loquercio and {Di Costanzo}, Gaetano and Flavio Fazioli and Michele Gallo and {De Chiara}, Annarosaria and Vincenzo Iervolino and Rosa Azzaro and Arnolfo Petruzziello and Antonio Mattiello and Carmela Cacciapuoti",
year = "2015",
month = "9",
day = "1",
language = "English",
volume = "29",
pages = "533--540",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Autologous platelet gel improves bone reconstruction of large defects in patients with Bone Giant Cell Tumors

AU - Loquercio, Giovanna

AU - Di Costanzo, Gaetano

AU - Fazioli, Flavio

AU - Gallo, Michele

AU - De Chiara, Annarosaria

AU - Iervolino, Vincenzo

AU - Azzaro, Rosa

AU - Petruzziello, Arnolfo

AU - Mattiello, Antonio

AU - Cacciapuoti, Carmela

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background/Aim: Giant cell tumors are mostly benign but locally aggressive tumors. The excision of bone tumors can result in large defects, therefore bone reconstruction is still one the most demanding procedures in orthopedic surgery. Our study addresses the opportunity for improving surgical outcome by employing β-Tricalcium phosphate (β-TCP) with platelet-rich plasma (PRP) at the surgical site. Patients and Methods: We included 16 patients with giant cell tumors. After adjuvant therapy, the cavity was reconstructed with β-TCP, bone graft material (ActifuserR Granules Baxter) and platelet gel application. Results: Our explorative analysis suggests a positive effect of PRP on surgical outcome in patients with giant cell tumors treated with curettage. Conclusion: Use of platelet gel as an adjuvant significantly reduces the time required for bone healing following intralesional treatment of benign giant cell tumors, and achieves good functional results without promoting local recurrence.

AB - Background/Aim: Giant cell tumors are mostly benign but locally aggressive tumors. The excision of bone tumors can result in large defects, therefore bone reconstruction is still one the most demanding procedures in orthopedic surgery. Our study addresses the opportunity for improving surgical outcome by employing β-Tricalcium phosphate (β-TCP) with platelet-rich plasma (PRP) at the surgical site. Patients and Methods: We included 16 patients with giant cell tumors. After adjuvant therapy, the cavity was reconstructed with β-TCP, bone graft material (ActifuserR Granules Baxter) and platelet gel application. Results: Our explorative analysis suggests a positive effect of PRP on surgical outcome in patients with giant cell tumors treated with curettage. Conclusion: Use of platelet gel as an adjuvant significantly reduces the time required for bone healing following intralesional treatment of benign giant cell tumors, and achieves good functional results without promoting local recurrence.

KW - Curettage

KW - Giant Cell Tumor Of Bone

KW - Growth Factors

KW - Loss Of Substance

KW - Platelet-Rich Plasma

KW - Regenerative Medicine

UR - http://www.scopus.com/inward/record.url?scp=84942111485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942111485&partnerID=8YFLogxK

M3 - Article

C2 - 26359411

AN - SCOPUS:84942111485

VL - 29

SP - 533

EP - 540

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 5

ER -